- Report
- January 2022
- 60 Pages
Global
From €3794EUR$3,950USD£3,266GBP
- Report
- January 2022
- 200 Pages
Global
From €7203EUR$7,500USD£6,202GBP
- Report
- January 2022
- 60 Pages
Global
From €3794EUR$3,950USD£3,266GBP
- Report
- January 2022
- 60 Pages
Global
From €3794EUR$3,950USD£3,266GBP
- Report
- January 2022
- 60 Pages
Global
From €3794EUR$3,950USD£3,266GBP
- Report
- August 2022
Global
From €759EUR$790USD£653GBP
- Report
- August 2022
United States
From €1863EUR$1,940USD£1,604GBP
- Report
- May 2022
- 354 Pages
Global
From €2401EUR$2,500USD£2,067GBP
- Report
- August 2022
- 70 Pages
Global
From €3357EUR$3,495USD£2,890GBP
- Clinical Trials
- January 2020
- 258 Pages
Global
From €2401EUR$2,500USD£2,067GBP
- Report
- July 2023
- 116 Pages
Global
From €3500EUR$3,904USD£3,119GBP
- Report
- July 2022
- 118 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Drug Pipelines
- October 2020
- 152 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- September 2023
- 200 Pages
Global
From €2880EUR$2,999USD£2,480GBP
The Urticaria Drug market is a subset of the Immune Disorders Drugs market, which focuses on the treatment of allergic reactions and other immune-related conditions. Urticaria, also known as hives, is a common skin condition characterized by itchy, raised welts on the skin. Urticaria drugs are used to reduce the symptoms of the condition, such as itching, swelling, and redness. These drugs can be administered orally, topically, or intravenously, depending on the severity of the condition. Commonly used urticaria drugs include antihistamines, corticosteroids, and leukotriene receptor antagonists.
Some companies in the Urticaria Drug market include GlaxoSmithKline, Sanofi, Novartis, Pfizer, and Merck. Show Less Read more
